Latest California Healthline Stories
Apoyo bipartidista a programa que ayuda a personas con VIH a tener vivienda
El programa otorgará $320 millones a zonas en las que el virus sigue expandiéndose. Tener un hogar seguro ayuda a llevar adelante un buen tratamiento.
Why A Pennsylvania Insurer’s Collapse Could Whack Californians In the Wallet
Little-known rules require all health insurance companies to help pay claims when any one of them fails. Penn Treaty failed big — and insurers around the country are likely to pass on those costs to policyholders. California consumers may be hit hardest.
Cuando las heridas no sanan, las terapias pueden costar hasta $5 mil millones
Cerca de 6,5 millones de personas en el país tienen heridas que tardan meses, y hasta años en sanar… si llegan a curarse. El costo, económico y psicológico, de estos padecimientos es astronómico.
When Wounds Won’t Heal, Therapies Spread — To The Tune Of $5 Billion
The market for wound care products booms among a growing older and diabetic patient pool, but many treatments are untested and funding for research falls short.
Despite Insurers’ Tactical Win On ACA’s Cost-Sharing Payments, Uncertainty Lingers
Court allows state attorneys general to join a pending legal challenge to keep billions in subsidies flowing to consumers and insurers, despite the Trump administration’s resistance.
Anthem’s Retreat Leaves Californians With Fewer Choices, More Worries
The nation’s second-largest insurer is shrinking its presence on Obamacare exchanges and in the broader individual market in response to prevailing uncertainty. California is just the latest — and the biggest — example.
Covered California Expects 12.5% Average Rate Rise In 2018
The figure could be higher if President Trump ends an important consumer subsidy, which he has threatened to do. Anthem Blue Cross will pull out of the exchange and the overall individual market in 16 of 19 regions in the state.
Denial, Appeal, Approval … An Adult’s Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Little-Known Middlemen Save Money On Medicines — But Maybe Not For You
Kaiser Health News examines the role of PBMs in the prescription drug-pricing pipeline.
Drug Puts A $750,000 ‘Price Tag On Life’
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.